Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DaVita names new senior vice president of federal legislative affairs
In this role, Mr Schaeffler will lead the organization’s public policy efforts in Washington, DC and report to DaVita CEO Kent Thiry. Prior to joining DaVita, Mr Schaeffler
In this role, Mr Schaeffler will lead the organization’s public policy efforts in Washington, DC and report to DaVita CEO Kent Thiry. Prior to joining DaVita, Mr Schaeffler
The diagnostic test is based on technology being developed by Antigen Express. The technology being developed at Antigen Express allows for more potent and specific activation of immune
According to Wound Management Technologies, CellerateRx is FDA cleared as a medical device and is indicated for all acute and chronic wounds except for third degree burns. Cathy
Affinity Capital Management led the round with Johnson & Johnson Development, L Capital Partners, and Clarian Health Ventures participating as first time investors. Existing investors, Prism VentureWorks, Three
Microline Pentax, a wholly owned subsidiary of Hoya and a manufacturer of reposable instruments for minimally invasive surgery, has acquired Starion Instruments, a developer of surgical technology for
The lawsuit contends that Davol’s recently released Sorbafix device infringes multiple claims of Covidien’s US patent. The patent generally relates to a system for controllably discharging fasteners from
These findings provide further evidence of mTOR as a validated cancer target with potential clinical applicability in several different tumor types, said Ariad. Deforolimus demonstrated potent single-agent, antitumor
The studies presented by the company further explore the detailed mechanism of action of LOR-253. The key findings include MTF-1 dependent induction of a novel tumor suppressor, namely
Among the several advancements announced in 2008 was the introduction on Oncentra Brachy, a new volume-based treatment planning solution that optimizes cancer treatment planning with brachytherapy. Additionally, Oncentra
First Quarter 2009: Gross margin was 50.1% versus 65.4% in the first quarter of 2008 Operating expenses were $13.1 million versus $13.2 million in the same period in